Spontaneous Hematoma With a Noncorrecting Mixing Study
A 74-year-old man presents with 2 weeks of easy bruising and a large spontaneous hematoma of the left thigh. He takes amlodipine and atorvastatin; he is on no anticoagulant, no antiplatelet agent, and no herbal supplements. Platelet count is 210 × 10^9/L, PT 12.8 s (reference 11.3–14.0), PTT 74 s (reference 25–35), fibrinogen 340 mg/dL. A 1:1 mixing study with normal pooled plasma gives a PTT of 70 s immediately and 78 s after 2 hours at 37°C. Factor VIII activity is 4%; factors IX, XI, XII, von Willebrand antigen and activity are normal, and von Willebrand multimers are normal. The Bethesda assay returns 8 BU/mL.
1. Classify the inhibitor from the mixing study, and explain why this is not a lupus anticoagulant.
Read the worked answer
Mixing study interpretation The PTT does not correct: 70 s immediately and 78 s after 2 hours, both far outside the reference interval. Failure to correct at 1:1 means an inhibitor is present rather than a simple factor deficiency.
The pattern is time- and temperature-dependent - the PTT rises with 2-hour incubation at 37°C. That is characteristic of a specific, low-titer, slowly binding antibody against a coagulation factor, classically factor VIII. An immediate-acting inhibitor that does not change with incubation suggests a nonspecific inhibitor.
Why not a lupus anticoagulant
- Lupus anticoagulants typically produce an immediate pattern that does not worsen with incubation.
- They prolong phospholipid-dependent tests without reducing a specific factor activity to a single-digit level in a 1:1 mix; factor VIII of 4% with all other factors normal points to one target.
- Clinically, lupus anticoagulants are associated with thrombosis, not with spontaneous deep bleeding and a large intramuscular hematoma.
Factor VIII activity of 4% plus a Bethesda titer of 8 BU/mL confirms acquired hemophilia A. The normal von Willebrand studies and absence of anticoagulants exclude the main mimics.
2. Why is the PTT a poor test for monitoring this patient, and how should therapy be guided instead?
Read the worked answer
Why the PTT fails as a monitoring tool
- The PTT is an indirect, phospholipid-dependent clotting time; it responds nonlinearly to factor VIII activity and does not reflect inhibitor neutralization once bypassing agents are in play.
- Bypassing agents (activated prothrombin complex concentrate, recombinant factor VIIa) act downstream of factor VIII and may shorten or paradoxically prolong the PTT depending on the reagent and dose; the result does not track hemostatic efficacy.
- Heparin contamination from line flushes, and the underlying inhibitor itself, both confound the result.
- The inhibitor titer, not the PTT, predicts the difficulty of achieving hemostasis.
What to monitor instead
- Clinical endpoints: bleeding cessation, hematoma size by imaging, hemoglobin and hemodynamic stability.
- Factor VIII activity by chromogenic assay when recombinant factor VIII is used, keeping in mind that the Bethesda assay and the chromogenic assay can diverge.
- Specific anti-Xa or thrombin-generation assays where available for bypassing agents.
- Watch for thrombosis - both bypassing agents and the underlying disease carry thrombotic risk, so a normal or shortened PTT is not a license to intensify therapy.
Therapeutic frame Stop the bleeding with an agent matched to titer (recombinant factor VIII for low-titer disease, a bypassing agent for high-titer disease) and start immunosuppression promptly - steroids with or without rituximab or cyclophosphamide - because the inhibitor is the disease. Delaying immunosuppression to see whether the hematoma resolves is a common and harmful error.
3. The patient's PTT normalizes after treatment. The team proposes stopping immunosuppression. What is your response?
Read the worked answer
PTT normalization is not a surrogate for inhibitor eradication, and stopping immunosuppression on that basis risks relapse.
Why the PTT is misleading here The PTT normalizes whenever factor VIII activity rises above roughly 30–40% - well below normal. Factor VIII is an acute-phase reactant and rises with inflammation, surgery, or the hematoma itself, so a normal PTT can occur while a meaningful inhibitor persists. Factor VIII activity of 40% with a residual inhibitor is a very different immunologic state from true remission.
What should define remission
- Undetectable inhibitor by Bethesda assay (or below the limit of detection) on at least two occasions.
- Factor VIII activity in the normal range off hemostatic support.
- No bleeding for a defined interval.
Practical approach Continue immunosuppression for the planned course, taper slowly, and monitor factor VIII activity and inhibitor titer at defined intervals after taper, since relapse is common and often occurs within the first 6 months. Counsel the patient on bleeding precautions and provide a written plan for urgent evaluation. Also recheck that the PTT normalization is not simply the acute-phase effect - a factor VIII level, not a PTT, should be the deciding data point.